Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LRRK2 | Q5S007 | 7/20 | 0.79 |
| ▸ | PSEN1 | P49768 | 3/20 | 0.79 |
| ▸ | PSEN2 | P49810 | 3/20 | 0.79 |
| ▸ | APH1B | Q8WW43 | 3/20 | 0.79 |
| ▸ | NCSTN | Q92542 | 3/20 | 0.79 |
| ▸ | APH1A | Q96BI3 | 3/20 | 0.79 |
| ▸ | PSENEN | Q9NZ42 | 3/20 | 0.79 |
| ▸ | PLK4 | O00444 | 2/20 | 0.70 |
| ▸ | PLK1 | P53350 | 1/20 | 0.70 |
| ▸ | ERBB2 | P04626 | 3/20 | 0.65 |
| ▸ | DHFR | P00374 | 1/20 | 0.61 |
| ▸ | EGFR | P00533 | 3/20 | 0.61 |
| ▸ | PDGFRB | P09619 | 1/20 | 0.61 |
| ▸ | RAF1 | P04049 | 3/20 | 0.61 |
| ▸ | AURKA | O14965 | 1/20 | 0.61 |
| ▸ | MDM2 | Q00987 | 1/20 | 0.60 |
| ▸ | MEN1 | O00255 | 1/20 | 0.59 |
| ▸ | PSMD14 | O00487 | 1/20 | 0.59 |
| ▸ | POLB | P06746 | 1/20 | 0.59 |
| ▸ | MMP2 | P08253 | 1/20 | 0.59 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1395329 | 1.00 | LRRK2 (0.79) | LRRK2PSEN1PSEN2APH1BNCSTN | |
| SCHEMBL1395360 | 0.89 | PLK4 (0.80) | LRRK2PSEN1PSEN2APH1BNCSTN | |
| SCHEMBL1394624 | 0.89 | PLK4 (0.80) | LRRK2PSEN1PSEN2APH1BNCSTN | |
| SCHEMBL1395363 | 0.89 | PLK4 (0.80) | LRRK2PSEN1PSEN2APH1BNCSTN | |
| SCHEMBL30578769 | 0.89 | PLK4 (0.80) | LRRK2PSEN1PSEN2APH1BNCSTN | |
| SCHEMBL1394626 | 0.89 | PLK4 (0.80) | LRRK2PSEN1PSEN2APH1BNCSTN | |
| SCHEMBL1395354 | 0.89 | LRRK2 (1.00) | LRRK2PSEN1PSEN2APH1BNCSTN | |
| SCHEMBL1395352 | 0.89 | LRRK2 (1.00) | LRRK2PSEN1PSEN2APH1BNCSTN | |
| SCHEMBL3800644 | 0.89 | LRRK2 (1.00) | LRRK2PSEN1PSEN2APH1BNCSTN | |
| SCHEMBL1394784 | 0.87 | RAF1 (0.79) | LRRK2PSEN1PSEN2APH1BNCSTN |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20160082015-A1 | METHODS, COMPOSITIONS AND KITS FOR PROMOTING MOTOR NEURON SURVIVAL AND TREATING AND DIAGNOSING NEURODEGENERATIVE DISORDERS | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2016-03-24 | — | — | US | disclosed |
| WO-2014172616-A2 | METHODS, COMPOSITIONS AND KITS FOR PROMOTING MOTOR NEURON SURVIVAL AND TREATING AND DIAGNOSING NEURODEGENERATIVE DISORDERS | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2014-10-23 | — | — | WO | disclosed |
| US-20120010178-A1 | METHODS AND COMPOUNDS FOR TREATMENT OF NEURODEGENERATIVE DISORDERS | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2012-01-12 | — | — | US | disclosed |
| WO-2010048273-A2 | METHODS AND COMPOUNDS FOR TREATMENT OF NEURODEGENERATIVE DISORDERS | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2010-04-29 | — | — | WO | disclosed |
| WO-2008021210-A2 | METHODS AND COMPOSITIONS FOR THE TREATMENT OF NEURODEGENERATIVE DISORDERS | COMBINATORX, INCORPORATED (US) | 2008-02-21 | — | — | WO | disclosed |
| US-20080044390-A1 | Methods and compositions for the treatment of neurodegenerative disorders | CHDI, INCORPORATED | 2008-02-21 | — | — | US | disclosed |
| US-6268391-B1 | Benzylidene-1,3-dihydro-indol-2-one derivatives a receptor tyrosine kinase inhibitors, particularly of Raf kinases | GLAXO WELLCOME INC. | 2001-07-31 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160082015-A1 | METHODS, COMPOSITIONS AND KITS FOR PROMOTING MOTOR NEURON SURVIVAL AND TREATING AND DIAGNOSING NEURODEGENERATIVE DISORDERS | SMN1; SMN2, SOD1, NEFM | LRRK2 392/4885PSEN1 23/4885PSEN2 20/4885 |
| US-20120010178-A1 | METHODS AND COMPOUNDS FOR TREATMENT OF NEURODEGENERATIVE DISORDERS | SMN1; SMN2, CLN6, SNCA | LRRK2 361/4885PSEN1 11/4885PSEN2 5/4885 |
| US-20080044390-A1 | Methods and compositions for the treatment of neurodegenerative disorders | HTT, SNCA, NLN | LRRK2 408/4885PSEN1 12/4885PSEN2 5/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.